PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025

Core Insights - PDS Biotechnology Corporation is a late-stage immunotherapy company focused on enhancing the immune system's ability to target and eliminate cancers [4] - The company will participate in a fireside chat at the B. Riley Securities Precision Oncology & Radiopharma Conference on February 28, 2025 [1][2] Company Overview - PDS Biotechnology is developing its lead investigational targeted immunotherapy, Versamune® HPV, in combination with a standard immune checkpoint inhibitor and a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate [4] - The company plans to initiate a pivotal clinical trial for advanced HPV16-positive head and neck squamous cell cancers [4] Event Details - The fireside chat will take place from 11:30 AM to 12:00 PM ET at the Lotte New York Palace Hotel, New York, NY [2] - PDS Biotech leadership will also conduct one-on-one meetings during the conference [2] Additional Information - An archived transcript of the fireside chat will be available on the company's Investor Relations section one week after the event [3]